Literature DB >> 30870563

Effect of the Serious Illness Care Program in Outpatient Oncology: A Cluster Randomized Clinical Trial.

Rachelle Bernacki1,2,3,4, Joanna Paladino1,3,4, Bridget A Neville3, Mathilde Hutchings2,3, Jane Kavanagh2,3, Olaf P Geerse3,5, Joshua Lakin1,2,4, Justin J Sanders1,2,3,4, Kate Miller3, Stuart Lipsitz3, Atul A Gawande1,3, Susan D Block1,2,3,4,6.   

Abstract

Importance: High-quality conversations between clinicians and seriously ill patients about values and goals are associated with improved outcomes but occur infrequently. Objective: To examine feasibility, acceptability, and effect of a communication quality-improvement intervention (Serious Illness Care Program) on patient outcomes. Design, Setting, and Participants: A cluster randomized clinical trial of the Serious Illness Care Program in an outpatient oncology setting was conducted. Patients with advanced cancer (n = 278) and oncology clinicians (n = 91) participated between September 1, 2012, and June 30, 2016. Data analysis was performed from September 1, 2016, to December 27, 2018. All analyses were conducted based on intention to treat. Interventions: Tools, training, and system changes. Main Outcomes and Measures: The coprimary outcomes included goal-concordant care (Life Priorities) and peacefulness (Peace, Equanimity, and Acceptance in the Cancer Experience questionnaire) at the end of life. Secondary outcomes included therapeutic alliance (Human Connection Scale), anxiety (Generalized Anxiety Disorder 7 scale), depression (Patient Health Questionnaire 9), and survival. Uptake and effectiveness of clinician training, clinician use of the conversation tool, and conversation duration were evaluated.
Results: Data from 91 clinicians in 41 clusters (72.9% participation; intervention, n = 48; control, n = 43; 52 [57.1%] women) and 278 patients (45.8% participation; intervention, n = 134; control, n = 144; 148 [53.2%] women) were analyzed. Forty-seven clinicians (97.9%) rated the training as effective (mean [SD] score, 4.3 [0.7] of 5.0 possible); of 39 who received a reminder, 34 (87.2%) completed at least 1 conversation (median duration, 19 minutes; range, 5-70). Peacefulness, therapeutic alliance, anxiety, and depression did not differ at baseline. The coprimary outcomes were evaluated in 64 patients; no significant differences were found between the intervention and control groups. However, the trial demonstrated significant reductions in the proportion of patients with moderate to severe anxiety (10.2% vs 5.0%; P = .05) and depression symptoms (20.8% vs 10.6%; P = .04) in the intervention group at 14 weeks after baseline. Anxiety reduction was sustained at 24 weeks (10.4% vs 4.2%; P = .02), but depression reduction was not sustained (17.8% vs 12.5%; P = .31). Survival and therapeutic alliance did not differ between groups. Conclusions and Relevance: The results of this cluster randomized clinical trial were null with respect to the coprimary outcomes of goal-concordant care and peacefulness at the end of life. Methodologic challenges for the primary outcomes, including measure selection and sample size, limit the conclusions that can be drawn from the study. However, the significant reductions in anxiety and depression in the intervention group are clinically meaningful and require further study. Trial Registration: ClinicalTrials.gov identifier: NCT01786811.

Entities:  

Mesh:

Year:  2019        PMID: 30870563      PMCID: PMC6547155          DOI: 10.1001/jamainternmed.2019.0077

Source DB:  PubMed          Journal:  JAMA Intern Med        ISSN: 2168-6106            Impact factor:   21.873


  54 in total

1.  Documentation of advance care planning for community-dwelling elders.

Authors:  Victoria Y Yung; Anne M Walling; Lillian Min; Neil S Wenger; David A Ganz
Journal:  J Palliat Med       Date:  2010-07       Impact factor: 2.947

2.  Estimate of current hospice and palliative medicine physician workforce shortage.

Authors:  Dale Lupu
Journal:  J Pain Symptom Manage       Date:  2010-12       Impact factor: 3.612

3.  Place of death: correlations with quality of life of patients with cancer and predictors of bereaved caregivers' mental health.

Authors:  Alexi A Wright; Nancy L Keating; Tracy A Balboni; Ursula A Matulonis; Susan D Block; Holly G Prigerson
Journal:  J Clin Oncol       Date:  2010-09-13       Impact factor: 44.544

4.  Defining High-Quality Palliative Care in Oncology Practice: An American Society of Clinical Oncology/American Academy of Hospice and Palliative Medicine Guidance Statement.

Authors:  Kathleen E Bickel; Kristen McNiff; Mary K Buss; Arif Kamal; Dale Lupu; Amy P Abernethy; Michael S Broder; Charles L Shapiro; Anupama Kurup Acheson; Jennifer Malin; Tracey Evans; Monika K Krzyzanowska
Journal:  J Oncol Pract       Date:  2016-08-16       Impact factor: 3.840

5.  A brief measure for assessing generalized anxiety disorder: the GAD-7.

Authors:  Robert L Spitzer; Kurt Kroenke; Janet B W Williams; Bernd Löwe
Journal:  Arch Intern Med       Date:  2006-05-22

6.  Barriers to goals of care discussions with seriously ill hospitalized patients and their families: a multicenter survey of clinicians.

Authors:  John J You; James Downar; Robert A Fowler; François Lamontagne; Irene W Y Ma; Dev Jayaraman; Jennifer Kryworuchko; Patricia H Strachan; Roy Ilan; Aman P Nijjar; John Neary; John Shik; Kevin Brazil; Amen Patel; Kim Wiebe; Martin Albert; Anita Palepu; Elysée Nouvet; Amanda Roze des Ordons; Nishan Sharma; Amane Abdul-Razzak; Xuran Jiang; Andrew Day; Daren K Heyland
Journal:  JAMA Intern Med       Date:  2015-04       Impact factor: 21.873

7.  Peace, Equanimity, and Acceptance in the Cancer Experience (PEACE): validation of a scale to assess acceptance and struggle with terminal illness.

Authors:  Jennifer W Mack; Matthew Nilsson; Tracy Balboni; Robert J Friedlander; Susan D Block; Elizabeth Trice; Holly G Prigerson
Journal:  Cancer       Date:  2008-06       Impact factor: 6.860

8.  Accountability for Community-Based Programs for the Seriously Ill.

Authors:  Joan M Teno; Russ Montgomery; Tom Valuck; Janet Corrigan; Diane E Meier; Amy Kelley; J Randall Curtis; Ruth Engelberg
Journal:  J Palliat Med       Date:  2017-12-01       Impact factor: 2.947

9.  Evaluating an Intervention to Improve Communication Between Oncology Clinicians and Patients With Life-Limiting Cancer: A Cluster Randomized Clinical Trial of the Serious Illness Care Program.

Authors:  Joanna Paladino; Rachelle Bernacki; Bridget A Neville; Jane Kavanagh; Stephen P Miranda; Marissa Palmor; Joshua Lakin; Meghna Desai; Daniela Lamas; Justin J Sanders; Jonathon Gass; Natalie Henrich; Stuart Lipsitz; Erik Fromme; Atul A Gawande; Susan D Block
Journal:  JAMA Oncol       Date:  2019-06-01       Impact factor: 31.777

Review 10.  Educational interventions to train healthcare professionals in end-of-life communication: a systematic review and meta-analysis.

Authors:  Han-Oh Chung; Simon J W Oczkowski; Louise Hanvey; Lawrence Mbuagbaw; John J You
Journal:  BMC Med Educ       Date:  2016-04-29       Impact factor: 2.463

View more
  51 in total

1.  Systematic Approach to Selecting and Preparing a Medical Power of Attorney in the Gynecologic Oncology Center.

Authors:  Donna S Zhukovsky; Pamela T Soliman; Boby Mathew; Sarah Mills; Diane Bodurka; Michael Frumovitz; Larissa A Meyer; Shannon Westin; Marisa Nowitz; LaShan Archie; Shauna Fenton; Kai Lang; Janet L Williams; Valentine Boving; Eduardo Bruera
Journal:  J Oncol Pract       Date:  2019-10-15       Impact factor: 3.840

2.  Integrating machine-generated mortality estimates and behavioral nudges to promote serious illness conversations for cancer patients: Design and methods for a stepped-wedge cluster randomized controlled trial.

Authors:  Christopher R Manz; Ravi B Parikh; Chalanda N Evans; Corey Chivers; Susan H Regli; Justin E Bekelman; Dylan Small; Charles A L Rareshide; Nina O'Connor; Lynn M Schuchter; Lawrence N Shulman; Mitesh S Patel
Journal:  Contemp Clin Trials       Date:  2020-01-23       Impact factor: 2.226

3.  Addressing serious illness conversations during COVID-19.

Authors:  Giovanna Sirianni; Sarah Torabi
Journal:  Can Fam Physician       Date:  2020-07       Impact factor: 3.275

4. 

Authors:  Giovanna Sirianni; Sarah Torabi
Journal:  Can Fam Physician       Date:  2020-07       Impact factor: 3.275

5.  An Integrative Framework of Appraisal and Adaptation in Serious Medical Illness.

Authors:  Kathleen E Bickel; Cari Levy; Edward R MacPhee; Keri Brenner; Jennifer S Temel; Joanna J Arch; Joseph A Greer
Journal:  J Pain Symptom Manage       Date:  2020-05-21       Impact factor: 3.612

Review 6.  Quality of clinicians' conversations with patients and families before and after implementation of the Serious Illness Care Program in a hospital setting: a retrospective chart review study.

Authors:  Christina Ma; Lauren E Riehm; Rachelle Bernacki; Joanna Paladino; John J You
Journal:  CMAJ Open       Date:  2020-06-19

Review 7.  Strategies for introducing palliative care in the management of relapsed or refractory aggressive lymphomas.

Authors:  Oreofe O Odejide
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

Review 8.  Emotions in the room: common emotional reactions to discussions of poor prognosis and tools to address them.

Authors:  Heather M Derry; Andrew S Epstein; Wendy G Lichtenthal; Holly G Prigerson
Journal:  Expert Rev Anticancer Ther       Date:  2019-08-10       Impact factor: 4.512

9.  Development and Validation of the ACP-CAT for Assessing the Quality of Advance Care Planning Communication.

Authors:  Jacqueline K Yuen; Amy S Kelley; Laura P Gelfman; Elizabeth E Lindenberger; Cardinale B Smith; Robert M Arnold; Brook Calton; Jane Schell; Stephen H Berns
Journal:  J Pain Symptom Manage       Date:  2019-09-11       Impact factor: 3.612

Review 10.  Conceptualizing and Counting Discretionary Utilization in the Final 100 Days of Life: A Scoping Review.

Authors:  Paul R Duberstein; Michael Chen; Michael Hoerger; Ronald M Epstein; Laura M Perry; Sule Yilmaz; Fahad Saeed; Supriya G Mohile; Sally A Norton
Journal:  J Pain Symptom Manage       Date:  2019-10-19       Impact factor: 3.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.